nasdaq.com
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment - Nasdaq
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative colitis, so clinicians and patients will be interested in how it compares to existing therapies.
Adults with moderate-to-severe Crohn's disease, patients considering or on biologic therapy, gastroenterologists and IBD clinicians, and researchers focused on IL-23–targeted treatments.
What To Know
The FDA has approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn's disease. This is the same IL-23p19–targeting biologic that Lilly previously had approved for ulcerative colitis.
The article reports that Omvoh reduces gut inflammation by targeting interleukin-23p19 and notes Lilly submitted global regulatory applications and disclosed two-year Phase 3 efficacy data at approval. Practical context: This approval adds another FDA-approved biologic option for adults with moderate-to-severe Crohn's disease.
It may be most relevant to people considering biologic therapies, clinicians who prescribe IBD treatments, and researchers tracking IL-23–targeting drugs. The Nasdaq piece is a brief news report summarizing Lilly's announcement and does not include detailed trial results, safety information, or prescribing guidance.
Next steps if you want details: Look for the FDA approval letter, Lilly's full press release, and peer-reviewed Phase 3 publications or conference presentations to see detailed efficacy, safety, and recommended dosing information.
The article is a short Nasdaq summary of RTTNews/Lilly announcements and does not include detailed trial data, safety profiles, or prescribing information. For clinical decisions, consult the FDA labeling and peer-reviewed trial reports. Regulatory approvals in other regions are pending.
